Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Fulvestrant 125Trastuzumab 115Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Anastrozole 72Capecitabine 71Cyclophosphamide 69Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 61trastuzumab deruxtecan 58Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 48Magnetic Resonance Spectroscopy 48Docetaxel 48Blood Specimen Collection 40olaparib 39Standard of Care 37Biopsy 34sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Exercise 29Doxorubicin 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × crenigacestat × 1 year × Clear all
NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡